Information updates

New 2023 versions of ASCIA Action Plans for Anaphylaxis

ASCIA has developed new 2023 versions of ASCIA Action Plans for Anaphylaxis, to improve ease of use, which will be available from June 2023. This is the first major formatting change in 20 years, since ASCIA Action Plans for Anaphylaxis were first introduced in 2003. The plans can be accessed on the ASCIA website:

Whilst the signs of, and actions for anaphylaxis are unchanged, other updates have been made to improve ease of use:

  1. Patient specific details are all completed in the top section.* 
  2. Signs of, and actions for mild to moderate allergic reactions are in two easy to follow lists. 
  3. Instructions for adrenaline injectors are colour coded.
  4. Instructions for both adrenaline injectors are included in the General version of the plan.
  5. Device specific versions of the plan for Anapen® and EpiPen® include changes 1-3 listed above and a QR code which links to short animated videos with adrenaline injector instructions.

* This formatting may also facilitate use with some EMR systems, subject to approval by ASCIA.  

The format of the following plans have also been updated to be consistent with the 2023 versions of the red ASCIA Action Plan for Anaphylaxis:

  • ASCIA Action Plan for Allergic Reactions (green)
  • ASCIA Action Plan for Drug (Medication) Allergy (dark green)
  • ASCIA First Aid Plan for Anaphylaxis (orange)

 A summary of updates is available here.

pdfASCIA Action Plan for Anaphylaxis 2023 - What's New431.38 KB

pdfASCIA Action Plan Allergic Reactions 2023 - What's New321.66 KB

pdfASCIA Action Plan Drug Allergy 2023 - What's New338.87 KB

pdfASCIA First Aid Plan Anaphylaxis 2023 - What's New415.79 KB 

Updates will be made to ASCIA e-training courses in  July 2023. Previous versions of ASCIA Action Plans (2021 and 2022 versions) can still be used in 2023, as we expect that it will take around six  months to phase in the use of the new 2023 plans.

Suppliers of Anapen and EpiPen will be printing the new plans, for prescribers who prefer to complete a printed version.

This news item was issued on 8 May 2023 and updated on 29 May 2023 by Jill Smith, CEO of the Australasian Society of Clinical Immunology and Allergy (ASCIA). ASCIA is the peak professional body for clinical immunology and allergy in Australia and New Zealand. 

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia